Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-009854
Filing Date
2025-03-11
Accepted
2025-03-11 16:20:21
Documents
61
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 564666
2 ex31-1.htm EX-31.1 9659
3 ex31-2.htm EX-31.2 9716
4 ex32-1.htm EX-32.1 3700
5 ex32-2.htm EX-32.2 3684
  Complete submission text file 0001493152-25-009854.txt   3795720

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE anix-20250131.xsd EX-101.SCH 31464
7 XBRL CALCULATION FILE anix-20250131_cal.xml EX-101.CAL 43415
8 XBRL DEFINITION FILE anix-20250131_def.xml EX-101.DEF 150202
9 XBRL LABEL FILE anix-20250131_lab.xml EX-101.LAB 270923
10 XBRL PRESENTATION FILE anix-20250131_pre.xml EX-101.PRE 219126
64 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 499833
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 25727884
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)